Ocular Therapeutix, Inc.
OCUL
$11.87
-$0.43-3.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.46M | 10.70M | 17.08M | 15.43M | 16.44M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.46M | 10.70M | 17.08M | 15.43M | 16.44M |
| Cost of Revenue | 53.03M | 44.12M | 42.22M | 38.62M | 30.37M |
| Gross Profit | -39.57M | -33.42M | -25.14M | -23.19M | -13.93M |
| SG&A Expenses | 28.08M | 30.50M | 25.44M | 22.81M | 20.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.10M | 74.62M | 67.66M | 61.42M | 51.33M |
| Operating Income | -67.64M | -63.92M | -50.58M | -46.00M | -34.89M |
| Income Before Tax | -67.81M | -64.05M | -48.39M | -36.49M | -43.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -67.81M | -64.05M | -48.39M | -36.49M | -43.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.81M | -64.05M | -48.39M | -36.49M | -43.78M |
| EBIT | -67.64M | -63.92M | -50.58M | -46.00M | -34.89M |
| EBITDA | -66.62M | -62.94M | -49.62M | -45.04M | -33.93M |
| EPS Basic | -0.39 | -0.38 | -0.29 | -0.22 | -0.26 |
| Normalized Basic EPS | -0.25 | -0.24 | -0.18 | -0.14 | -0.13 |
| EPS Diluted | -0.39 | -0.38 | -0.29 | -0.22 | -0.26 |
| Normalized Diluted EPS | -0.25 | -0.24 | -0.18 | -0.14 | -0.13 |
| Average Basic Shares Outstanding | 172.59M | 169.40M | 168.02M | 166.99M | 165.82M |
| Average Diluted Shares Outstanding | 172.59M | 169.40M | 168.02M | 166.99M | 165.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |